By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics company T2 Biosystems today said it has closed its $23 million Series D financing round.

The funds will be used to support ongoing clinical trials and technology development as the company prepares to seek regulatory approval and commercialization of its T2MR diagnostic technology based on magnetic biosensor detection. The funding will also allow it to expand its partnering program, the Lexington, Mass.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.